(Reuters) – The U.S. Food and Drug Administration approved Eli Lilly and Co’s treatment for severe hypoglycemia, the health regulator said on Wednesday. Hypoglycemia is a condition in which blood sugar falls to dangerously low levels. Severe hypoglycemia typically occurs in people with diabetes who are using insulin treatment, the FDA said and noted that the therapy – Baqsimi – is approved to treat the severe form of the condition in patients with diabetes aged four and older.  Full article